NTRK1 and renal cell carcinoma: It was later shown that the anti-angiogenic drug sunitinib, which inhibits multiple receptor tyrosine kinases, induces lymphangiogenesis in renal cell carcinoma (RCC) by inducing VEGFC expression which was associated with increased LN metastasis (Dufies et al., 2017).